Top Page
Dr. Martens Plc
(LSE:DOCS)
Dr. Martens Plc (DOCS) vs. iShares MSCI United Kingdom ETF (EWC)
Dr. Martens Plc Business Overview & Revenue Model
Dr. Martens Plc Earnings Call Summary
Dr. Martens Plc Financial Statement Overview
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 805.90M | 877.10M | 1.00B | 908.30M | 773.00M | 672.20M |
| Gross Profit | 528.00M | 502.90M | 563.90M | 542.10M | 436.70M | 372.60M |
| EBITDA | 84.40M | 197.50M | 204.40M | 266.00M | 145.10M | 183.50M |
| Net Income | 29.40M | 69.20M | 128.90M | 181.20M | 34.70M | 74.80M |
Balance Sheet | ||||||
| Total Assets | 932.40M | 952.40M | 992.60M | 859.10M | 651.80M | 656.50M |
| Cash, Cash Equivalents and Short-Term Investments | 94.90M | 111.10M | 157.50M | 228.00M | 113.60M | 117.20M |
| Total Debt | 449.70M | 468.60M | 445.80M | 393.80M | 366.40M | 495.60M |
| Total Liabilities | 597.90M | 584.20M | 588.40M | 530.90M | 502.10M | 586.00M |
| Stockholders Equity | 334.50M | 368.20M | 404.20M | 328.20M | 149.70M | 70.50M |
Cash Flow | ||||||
| Free Cash Flow | 216.10M | 139.50M | 20.30M | 148.60M | 128.80M | 94.10M |
| Operating Cash Flow | 226.70M | 167.90M | 71.70M | 173.60M | 146.10M | 116.00M |
| Investing Cash Flow | -21.50M | -25.50M | -52.20M | -25.00M | -17.30M | -21.90M |
| Financing Cash Flow | -142.10M | -185.90M | -92.30M | -36.20M | -120.10M | -38.60M |
Dr. Martens Plc Technical Analysis
Dr. Martens Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £1.29B | 7.07 | 5.01% | ― | -10.46% | 396.13% | |
71 Outperform | £6.82B | 23.14 | 10.25% | 1.10% | 6.87% | 22.36% | |
67 Neutral | £737.99M | 162.77 | 1.23% | 2.19% | -17.55% | -71.22% | |
62 Neutral | $16.76B | 11.38 | -7.38% | 2.96% | 1.59% | -23.30% | |
58 Neutral | £494.80M | ― | -27.20% | ― | -14.37% | -28.78% | |
50 Neutral | £367.59M | ― | -62.59% | ― | -15.86% | -18.46% | |
48 Neutral | £260.02M | ― | -96.36% | ― | -16.32% | -202.39% |
Dr. Martens Plc Corporate Events
Dr. Martens Plc has announced its total voting rights, with an issued ordinary share capital consisting of 965,190,393 shares, each carrying one voting right. This disclosure is in line with FCA’s rules and helps shareholders determine their notification requirements regarding their interests in the company, impacting transparency and stakeholder engagement.
Spark’s Take on GB:DOCS Stock
According to Spark, TipRanks’ AI Analyst, GB:DOCS is a Neutral.
Dr. Martens scores a 66, reflecting a mixed financial performance with strong cash flow and moderate leverage. Technical indicators present a bearish view, and valuation appears fair. Positive corporate events provide optimism, but the overall outlook is tempered by declining revenues and profitability margins.
To see Spark’s full report on GB:DOCS stock, click here.
Dr. Martens Plc has announced a transaction involving its Chief Executive Officer, Ije Nwokorie, related to the vesting of restricted stock units (RSUs) under the company’s Long Term Incentive Plan. The RSUs were granted to Nwokorie as part of a buyout arrangement when he joined the company, and a portion of these shares were sold to cover his tax and national insurance liabilities. This transaction reflects the company’s adherence to its Remuneration Policy and highlights its commitment to transparent executive compensation practices.
Spark’s Take on GB:DOCS Stock
According to Spark, TipRanks’ AI Analyst, GB:DOCS is a Neutral.
Dr. Martens Plc scores a 66, reflecting a mixed financial performance with strong cash flow but declining revenue and profitability. Technical indicators suggest bearish trends, while valuation remains reasonable with a solid dividend yield. Positive corporate events provide some optimism, though challenges in profitability and technical performance are significant.
To see Spark’s full report on GB:DOCS stock, click here.
Dr. Martens plc has announced transactions involving its directors under the company’s Share Incentive Plan (SIP). On April 11, 2025, CEO Ije Nwokorie and CFO Giles Wilson acquired Partnership Shares and were granted Matching Shares, reflecting the company’s commitment to employee investment and engagement. These transactions, conducted on the London Stock Exchange, highlight Dr. Martens’ efforts to align management interests with shareholder value, potentially impacting stakeholder confidence positively.
Spark’s Take on GB:DOCS Stock
According to Spark, TipRanks’ AI Analyst, GB:DOCS is a Neutral.
Dr. Martens Plc scores a 65, reflecting a balance of mixed financial performance, challenging technical indicators, and reasonable valuation. The company’s strong cash flow and strategic corporate events provide optimism, though declining revenue and weak technical signals pose concerns.
To see Spark’s full report on GB:DOCS stock, click here.
Dr. Martens plc announced transactions involving its Share Incentive Plan (SIP), where directors and persons discharging managerial responsibilities acquired shares. The SIP allows employees to purchase shares from their salary and receive matching shares from the company, demonstrating Dr. Martens’ commitment to employee investment and engagement. This initiative reflects the company’s strategy to align employee interests with corporate performance, potentially enhancing stakeholder value.
Spark’s Take on GB:DOCS Stock
According to Spark, TipRanks’ AI Analyst, GB:DOCS is a Neutral.
Dr. Martens Plc receives an overall score of 64, reflecting a balance of mixed financial performance, weak technical indicators, reasonable valuation, and positive corporate developments. While the company shows strong cash flow and stable leverage, the decline in revenue and profitability margins remains a concern. Positive corporate events and a solid dividend yield offer some optimism for future performance.
To see Spark’s full report on GB:DOCS stock, click here.
Dr. Martens Plc has announced its total voting rights, with the company’s issued ordinary share capital consisting of 964,537,323 shares, each with one voting right. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
Dr. Martens plc announced a transaction involving its Chief Financial Officer, Giles Wilson, who received a cash payment as part of his buyout arrangements. In accordance with the company’s remuneration policy, a portion of this payment was used to purchase shares, which Wilson is required to hold for a minimum of two years. This transaction aligns with the company’s commitment to ensuring managerial responsibility and adherence to market regulations, potentially reinforcing investor confidence.
Dr. Martens Plc announced that its directors and persons discharging managerial responsibility have participated in the company’s Share Incentive Plan (SIP), purchasing Partnership Shares and receiving Matching Shares. This initiative, approved by HMRC, allows employees to buy shares from their monthly salary and receive additional shares from the company, aligning employee interests with company performance.
Dr. Martens Plc has announced that its total voting rights stand at 964,498,789 ordinary shares, each with a voting right, as per the FCA’s Disclosure Guidance and Transparency Rule. This information is crucial for shareholders to determine their interests and any changes in their stakes in the company, impacting their decision-making and compliance with regulatory requirements.
Dr. Martens plc has announced a series of share transactions involving its directors under the company’s Share Incentive Plan (SIP). These transactions allow employees to purchase shares from their salary and receive matching shares from the company. On February 11, 2025, both the CEO, Ije Nwokorie, and CFO, Giles Wilson, participated in this plan, acquiring 207 Partnership Shares each and receiving 207 Matching Shares. This initiative reinforces the company’s commitment to employee investment in its growth and aligns the interests of its leadership with those of its shareholders.
Dr. Martens plc has announced the appointment of Robert Hanson and Benoit Vauchy as Non-Executive Directors, effective from March 26, 2025. Robert Hanson brings extensive experience in consumer brand growth, having held senior roles at John Hardy and American Eagle Outfitters, among others, while Benoit Vauchy is a seasoned financial leader from Permira, the company’s largest investor. These appointments are expected to enhance the board’s expertise, with a focus on navigating the next phase of the company’s evolution under its current leadership.